Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by 1620 Investment Advisors Inc.

1620 Investment Advisors Inc. grew its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 230.1% during the third quarter, Holdings Channel reports. The firm owned 2,212 shares of the company’s stock after purchasing an additional 1,542 shares during the period. 1620 Investment Advisors Inc.’s holdings in Omnicell were worth $96,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of OMCL. Arizona State Retirement System raised its stake in Omnicell by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after acquiring an additional 357 shares in the last quarter. Texas Permanent School Fund Corp grew its holdings in shares of Omnicell by 1.2% during the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after purchasing an additional 479 shares during the last quarter. Diversified Trust Co increased its position in shares of Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after purchasing an additional 494 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. Finally, Louisiana State Employees Retirement System boosted its position in shares of Omnicell by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after purchasing an additional 600 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Wells Fargo & Company upped their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $26.00 to $39.00 in a research report on Friday, August 2nd. Benchmark reaffirmed a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a report on Saturday, October 19th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Omnicell Stock Up 32.2 %

Shares of Omnicell stock opened at $53.05 on Thursday. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74. The company has a market cap of $2.44 billion, a P/E ratio of -115.33, a PEG ratio of 43.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The firm has a fifty day moving average of $43.14 and a two-hundred day moving average of $35.07.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. During the same period in the prior year, the company posted $0.29 earnings per share. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. On average, analysts forecast that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.